CR20170104A - Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr - Google Patents
Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfrInfo
- Publication number
- CR20170104A CR20170104A CR20170104A CR20170104A CR20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A CR 20170104 A CR20170104 A CR 20170104A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fgfr
- treatment
- cancer patients
- responsive
- mutant gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente descripción, se describen métodos para identificar un paciente con cáncer que responderá al tratamiento con un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR) y métodos para tratar pacientes con cáncer. Los métodos implican evaluar una muestra biológica del paciente para detectar la presencia de uno o más mutantes de FGFR a partir de un panel de genes mutantes de FGFR. En la presente descripción se describen, además, estuches e iniciadores para identificar la presencia de uno o más genes mutantes de FGFR en una muestra biológica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/050996 WO2016048833A2 (en) | 2014-09-26 | 2015-09-18 | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170104A true CR20170104A (es) | 2017-05-31 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170104A CR20170104A (es) | 2014-09-26 | 2015-09-18 | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20160090633A1 (es) |
| EP (2) | EP4063516A1 (es) |
| JP (4) | JP6766037B2 (es) |
| KR (3) | KR102839867B1 (es) |
| CN (2) | CN113957146A (es) |
| AR (1) | AR102345A1 (es) |
| AU (3) | AU2015321626B2 (es) |
| CA (1) | CA2962075C (es) |
| CO (1) | CO2017003528A2 (es) |
| CR (1) | CR20170104A (es) |
| CY (1) | CY1125190T1 (es) |
| DK (1) | DK3198033T3 (es) |
| EA (1) | EA037920B1 (es) |
| EC (1) | ECSP17025787A (es) |
| ES (1) | ES2912567T3 (es) |
| GT (1) | GT201700059A (es) |
| HR (1) | HRP20220496T1 (es) |
| HU (1) | HUE058219T2 (es) |
| IL (3) | IL251264B (es) |
| JO (1) | JO3681B1 (es) |
| LT (1) | LT3198033T (es) |
| MA (1) | MA40761B1 (es) |
| MX (2) | MX392774B (es) |
| MY (1) | MY194567A (es) |
| NI (1) | NI201700035A (es) |
| PH (1) | PH12017500556A1 (es) |
| PL (1) | PL3198033T3 (es) |
| PT (1) | PT3198033T (es) |
| RS (1) | RS63178B1 (es) |
| SG (1) | SG11201702381QA (es) |
| SI (1) | SI3198033T1 (es) |
| SM (1) | SMT202200177T1 (es) |
| SV (1) | SV2017005415A (es) |
| TW (1) | TWI706136B (es) |
| UA (1) | UA122564C2 (es) |
| UY (1) | UY36325A (es) |
| WO (1) | WO2016048833A2 (es) |
| ZA (1) | ZA201702899B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643571T3 (es) | 2012-09-27 | 2017-11-23 | Chugai Seiyaku Kabushiki Kaisha | Gen de fusión FGFR3 y fármaco que se dirige al mismo |
| JP6731254B2 (ja) | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| KR102839867B1 (ko) | 2014-09-26 | 2025-07-28 | 얀센 파마슈티카 엔브이 | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR20250007056A (ko) * | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP4130749A1 (en) | 2018-07-27 | 2023-02-08 | Zepto Life Technology, LLC | System and method for sample preparation in gmr-based detection of biomarkers |
| JP7761485B2 (ja) * | 2018-09-21 | 2025-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 胆管癌の処置 |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| WO2020201138A1 (en) | 2019-03-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| CA3130460A1 (en) | 2019-03-29 | 2020-10-08 | Anne Elizabeth O'HAGAN | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| MX2021014524A (es) * | 2019-05-31 | 2022-05-19 | Qed Therapeutics Inc | Metodos para tratar canceres del sistema urinario. |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| CN114341187A (zh) * | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | 抗突变型fgfr3抗体及其用途 |
| WO2021050100A1 (en) * | 2019-09-09 | 2021-03-18 | Zepto Life Technology, LLC | Systems and methods for detecting genetic variation in nucleic acids |
| EP4034118A1 (en) | 2019-09-26 | 2022-08-03 | Janssen Pharmaceutica NV | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| TWI900527B (zh) | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| BR112022015827A2 (pt) | 2020-02-12 | 2022-10-04 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco |
| BR112022020846A2 (pt) * | 2020-04-15 | 2022-12-27 | Alkermes Pharma Ireland Ltd | Agentes imunoestimuladores em combinação com inibidores de angiogênese |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| CA3191538A1 (en) | 2020-09-14 | 2022-03-17 | Ademi Elena SANTIAGO-WALKER | Fgfr inhibitor combination therapies |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| BR112023023935A2 (pt) | 2021-05-19 | 2024-01-30 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase de fgfr para o tratamento de tumores sólidos avançados |
| JP2024538993A (ja) | 2021-10-12 | 2024-10-28 | タリス バイオメディカル エルエルシー | エルダフィチニブ製剤及び膀胱内投与のためのシステム |
| JP2025507590A (ja) | 2022-02-18 | 2025-03-21 | タリス バイオメディカル エルエルシー | エルダフィチニブ製剤及び膀胱内投与のための浸透圧システム |
| WO2024173377A1 (en) | 2023-02-13 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
| CN120813357A (zh) | 2023-02-13 | 2025-10-17 | 詹森药业有限公司 | 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂 |
| WO2024173716A1 (en) | 2023-02-17 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
| WO2025059602A1 (en) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Methods of treating bladder cancer using intravesical administration of erdafitinib |
| CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000068424A2 (en) | 1999-05-05 | 2000-11-16 | Institut Curie | Means for detecting and treating pathologies linked to fgfr3 |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| JP4649331B2 (ja) | 2002-10-01 | 2011-03-09 | エピゲノミクス アーゲー | 乳房細胞増殖障害の改良治療方法および核酸 |
| DE602004022266D1 (de) * | 2003-03-26 | 2009-09-10 | Progenika Biopharma Sa | Lkarzinoms der blase |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (en) * | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| BRPI0619548A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | efeitos inibidores de fgfr3 em transcrição de gene |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| AU2008220821B2 (en) | 2007-02-27 | 2012-09-13 | Novartis Ag | A method of identification of cells that show sensitivity to modulation of signaling mediated by a Fibroblast Growth Factor Receptor or a variant thereof |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| CA2691451C (en) | 2007-06-21 | 2015-03-24 | Sara H. Fan | Instrument and receptacles for performing processes |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| WO2013173485A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancers |
| WO2013173480A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancer recurrence |
| GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| JP2012521768A (ja) | 2009-03-27 | 2012-09-20 | ジモジェネティクス・インコーポレイテッド | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
| WO2011027219A1 (en) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of small genomic deletions and insertions |
| US9140689B2 (en) * | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| CN103906848B (zh) | 2011-08-18 | 2016-03-02 | 雀巢产品技术援助有限公司 | 用于检测等位变体的组合物和方法 |
| US20130096021A1 (en) | 2011-09-27 | 2013-04-18 | Arul M. Chinnaiyan | Recurrent gene fusions in breast cancer |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| JP5343177B1 (ja) * | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
| HK1205528A1 (en) | 2012-03-08 | 2015-12-18 | Astellas Pharma Inc. | Novel fgfr3 fusion product |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2871236A4 (en) * | 2012-07-05 | 2016-03-09 | Nat Cancer Ct | FGFR2 fusion |
| KR102132149B1 (ko) * | 2012-07-24 | 2020-07-09 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 융합 단백질 및 그의 방법 |
| RU2015102194A (ru) * | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
| ES2643571T3 (es) * | 2012-09-27 | 2017-11-23 | Chugai Seiyaku Kabushiki Kaisha | Gen de fusión FGFR3 y fármaco que se dirige al mismo |
| CA2890346A1 (en) * | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP3939614A1 (en) * | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US9777333B2 (en) | 2013-04-05 | 2017-10-03 | Life Technologies Corporation | Gene fusion |
| US20160186269A1 (en) | 2013-05-27 | 2016-06-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Novel translocations in lung cancer |
| US9783853B2 (en) | 2013-07-12 | 2017-10-10 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
| US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| KR102839867B1 (ko) | 2014-09-26 | 2025-07-28 | 얀센 파마슈티카 엔브이 | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| JOP20190190A1 (ar) | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2015
- 2015-09-18 KR KR1020227040649A patent/KR102839867B1/ko active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 KR KR1020257024958A patent/KR20250119657A/ko active Pending
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en not_active Ceased
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 CA CA2962075A patent/CA2962075C/en active Active
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-23 IL IL291633A patent/IL291633B1/en unknown
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
- 2025-11-06 IL IL324511A patent/IL324511A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170104A (es) | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| CO7151491A2 (es) | Método para la identificación del origen de un cancer de origen primario desconocido | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| HK1255533A1 (zh) | 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板 | |
| MY195860A (en) | Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor | |
| NZ601606A (en) | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors | |
| EP4249608A3 (en) | Early lung cancer detection by dna methylation phenotyping of sputum-derived cells | |
| PH12017501064A1 (en) | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor | |
| MX2021003320A (es) | Tratamiento del colangiocarcinoma. | |
| PL408727A1 (pl) | Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena | |
| LV14878A (lv) | Vairogdziedzera papillāra vēža riska noteikšanas paņēmiens pacientiem ar vairogdziedzera mezgliem | |
| EA201992849A1 (ru) | Ингибиторы fgfr2 для лечения холангиокарциномы | |
| UA92857U (uk) | Спосіб ранньої діагностики дисметаболічних порушень, метаболічного синдрому-х у працівників локомотивних бригад | |
| UA92246U (ru) | Спектрофотометрический способ количественного определения зопиклона | |
| AR104791A1 (es) | Métodos terapéuticos y diagnósticos para el cáncer | |
| PE20142434A1 (es) | Metodo para la identificacion del origen de un cancer de origen primario desconocido | |
| UA96044U (uk) | Спосіб прогнозування зрощення перелому |